Welcome to our dedicated page for SenesTech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SenesTech, Inc. filings document the public-company records of a Nasdaq-listed developer of fertility-control products for rodent and animal pest management. Recent Form 8-K reports cover operating results, commercial updates tied to e-commerce and Evolve products, and material governance events involving executive appointments, departures, employment terms, and compensation arrangements.
SenesTech proxy materials describe annual meeting matters, board and executive compensation disclosures, shareholder voting items, and governance information. The filings also identify the company’s registered common stock, par value, trading symbol SNES, and Nasdaq listing, providing formal disclosure around capital structure and corporate administration.
SenesTech, Inc. (SNES) reported that Chief Executive Officer and director Michael Edell purchased a total of 2,000 shares of common stock on September 9, 2026 in open-market transactions, with 1,000 shares bought at $0.89 per share and 1,000 shares bought at $0.85 per share. No Rule 10b5-1 trading plan is reported for these purchases.
SenesTech, Inc. insider Michael Edell, the Chief Executive Officer and a director, reported a purchase of SenesTech common stock. On 2026-08-14, he bought 1,000 shares at a price of $1.21 per share. After this open-market or private transaction, he directly owns 6,000 shares of common stock.
Glenbrook Capital Management, a more than ten percent owner of SenesTech, Inc., reported two open-market purchases of common stock held in an account it manages. On 2026-08-06 it purchased 15,000 shares at $1.2962 per share, and on 2026-08-07 it purchased 6,490 shares at $1.2977 per share. After these indirect purchases, the managed account held 1,079,294 SenesTech common shares. Glenbrook Capital Management serves as investment manager to the account and disclaims beneficial ownership except to the extent of its pecuniary interest. The transactions were not reported as made under a Rule 10b5-1 trading plan.
SenesTech, Inc. reports higher sales but continued losses for the quarter ended June 30, 2026. Revenues were $770,000, up from $625,000 a year earlier, driven mainly by Evolve fertility-control products, which contributed 86% of quarterly revenue and increasingly flow through e-commerce channels such as Amazon. Six‑month revenue reached $1.3 million.
Gross margin strengthened to 73.6% as the company shifted Amazon sales to direct management, capturing higher unit pricing while recording marketplace fees in operating expenses. Operating expenses rose to $2.4 million in the quarter, reflecting leadership succession costs, higher professional fees, and commercialization investments, leading to a net loss of $1.8 million for the quarter and $3.9 million year‑to‑date.
Cash and cash equivalents were $5.1 million, down from $7.6 million at year‑end, after using $3.6 million in operating cash during the first half. Management expects existing cash plus anticipated revenue to fund operations only through the end of the first quarter of fiscal 2027 and plans to grow revenue, manage expenses, and raise additional capital, including through its at‑the‑market equity facility with roughly $7.3 million of remaining capacity. A prior legal dispute with Liphatech was settled and dismissed. Significant outstanding stock options and warrants represent potential future dilution.
SenesTech reported record Q2 2026 results, with revenue of $770,000, up 56% sequentially and 23% year over year, and a company-record gross margin of 73.6%. First-half 2026 revenue reached $1.26 million, a 14% increase versus the first half of 2025.
E-commerce was the main growth driver: revenue more than tripled to $511,000, including Amazon revenue of $349,000 in the first full quarter of in-house management, and subscription revenue of $104,000. Despite this, SenesTech posted a Q2 net loss of $1.8 million and Adjusted EBITDA loss of $1.4 million, with $5.1 million in cash at June 30, 2026. Management emphasized continued investment in its e-commerce platform, AI-enabled assessment services, targeted B2B verticals, agricultural deployments and international distribution while working toward profitability.
SenesTech, Inc. reported strong momentum in its e-commerce operations for the second quarter of 2026. The company said its active online subscription customer base, spanning both direct-to-consumer and business-to-business customers, more than doubled compared with the first quarter, reaching a record level and reinforcing its subscription-driven, recurring revenue model.
The company also stated that its e-commerce business grew 186% quarter over quarter, supported by investments in Amazon, SenesTech.com and its Shopify platform, including transitioning to direct management of these channels. Management highlighted that subscriptions for its Evolve® and ContraPest® rodent birth control products are designed to encourage ongoing product use and generate more predictable recurring revenue, with the strategy aimed at increasing customer lifetime value and strengthening long-term relationships across consumer and commercial markets.
Glenbrook Capital Management, a Nevada-based investment manager, reports beneficial ownership of 1,057,804 shares of SenesTech common stock, representing 19.95% of the 5,303,426 shares outstanding as of May 11, 2026.
Glenbrook acquired the position for approximately $3.6 million from its working capital through funds and managed accounts, viewing SenesTech as undervalued and an attractive investment. It also holds warrants in PFS Trust and an employee profit-sharing plan that are subject to 9.99% and 4.99% beneficial ownership blockers, limiting further exercises.
The firm characterizes the holding as an investment but has been, and may continue to be, actively engaged with SenesTech’s management, board and other shareholders on strategy, operations, marketing, capital structure and governance, and may increase or decrease its economic exposure over time.
Glenbrook Capital Management, a ten percent owner of SenesTech, Inc., reported purchasing 35,000 shares of common stock on July 20, 2026 at an average price of $1.4734 per share in an open-market or private transaction. Following this trade, an account it manages held 1,057,824 shares indirectly. Glenbrook states these securities are held for a managed account and it disclaims beneficial ownership except to the extent of its pecuniary interest. The transaction was not marked as being under a Rule 10b5-1 trading plan.
SenesTech, Inc. Chief Executive Officer Michael Edell reported an open-market purchase of 1,000 shares of Common Stock at about $1.43 per share. This buy increased his direct holdings to 5,000 shares, indicating a larger personal stake in the company’s equity.
SenesTech, Inc. reported an insider transaction involving an account managed by Glenbrook Capital Management, a ten percent owner. On June 30, 2026, the account made an open-market purchase of 35,000 shares of common stock at an average price of $1.5066 per share. Following this trade, the account indirectly holds 1,022,824 shares of SenesTech common stock. Glenbrook Capital Management serves as investment manager to the account and disclaims beneficial ownership of these securities except to the extent of its pecuniary interest, if any.